Alerts

WHITEHOUSE STATION, N.J., Oct. 17, 2006 — Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved JANUVIA™ (sitagliptin phosphate), the first and only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and …

Treatment with pioglitazone (Actos, Takeda/Eli Lilly and Co.) reduced stroke risk in patients with type 2 diabetes by 47% in patients with a prior history of stroke. Announced at the World Conference of Cardiology 2006.

Bayer HealthCare Diabetes Care Buys Metrika, the maker of the A1c disposal test. This makes Bayer the largest supplier of A1c testing products. Bayer’s DCA 2000 A1c analyzer is now joined by Metrika’s A1cNow+ available as a 10 pack for doctors offices and soon to be available for consumers sometime …

Dexcom Receives FDA Approval For STS(TM) Continuous Glucose Monitoring System – a first generation device designed to help people with diabetes more conveniently and effectively manage their blood sugar levels. This is the second CGMS that has hit the market, and you can expect at least one more this year. …

Why bother to be interested in Lilly’s re-introduction of Humalog 50/50? I look forward to this as it comes closer to mimicking the bodies own insulin release, and for my patients it reduces the chance of nocturnal hypoglycemia. Learn more about how this formulation makes a difference by checking out …

Novartis Nutrition Corporation Issues Nationwide Recall of One Lot of Its Diabetisource(R) AC Product – They are recalling 2,712 bottles of an enteral feeding formula which was incorrectly labeled as Diabetisource(R) AC 1.5 Liter bottles lot 2135L. More Information

Abbott Diabetes Care, a division of Abbott Laboratories , said late Friday that it has voluntarily initiated a correction and notification to users of its blood glucose meters in the U.S. Abbott’s blood glucose meters are designed to allow patients to display one of two standard units of measure: milligrams …

St. Petersburg Times, Dec 7, 2003 TheraSense Files Premarket Approval Application for Freestyle Navigator(TM) Continuous Glucose Monitor– The PMA filing follows recently presented clinical data on Navigator that included results of home-use trials involving 102 subjects at 7 clinical sites. FreeStyle Navigator is a continuous glucose monitor designed to replace …